Join the 'Lovenox' group to help and get support from people like you. How it works
Lovenox Blog
| Tweet |
Adding Lovenox Didn't Reduce Blood Clot Death Risk in Study
Posted 28 Dec 2011 by Drugs.com
WEDNESDAY, Dec. 28 – Severely ill hospital patients are at high risk for developing potentially fatal blood clots, and often wear compression stockings and/or take blood thinners to help lower this risk. However, adding the blood thinner Lovenox (enoxaparin) to the mix does not reduce their chances of dying from a blood clot, according to research appearing in the Dec. 29 issue of the New England Journal of Medicine. In the new study, almost 4,200 patients received Lovenox plus compression hose and more than 4,100 were given compression hose plus a placebo to lower their risk of developing a deep venous thrombosis (DVT). These blood clots tend to occur in the lower leg and thigh, where they can block blood flow and cause swelling and pain. If a clot dislodges – becoming an embolism – it can travel to the lungs or brain, resulting in organ damage and even death. After 30 days of ... Read more
Related support groups: Lovenox, Enoxaparin, Clexane, Clexane Forte, Lovenox HP
Generic Lovenox Approved for Deep Vein Thrombosis
Posted 23 Jul 2010 by Drugs.com
FRIDAY, July 23 – The first generic version of enoxaparin sodium injection (brand name: Lovenox), a blood-thinning drug designed to prevent deep vein thrombosis, has been approved by the U.S. Food and Drug Administration. The condition, abbreviated as DVT, can cause potentially deadly blot clots that form in veins deep within the body. Veins in the lower leg and thigh are most prone to the condition, the agency said in a news release. DVT-related clots have the potential to break away and travel to the lung, triggering a deadly blockage in a lung artery called a pulmonary embolism. About 100,000 cases of pulmonary embolism are reported each year in the United States, and it's the third-most common cause of death among people in the hospital, the FDA said. Lovenox, FDA-approved in 1993, is made from the blood-thinning drug heparin. The makers of generic drugs that earn the agency's ... Read more
Related support groups: Lovenox, Enoxaparin, Clexane, Clexane Forte, Lovenox HP
Many Dialysis Patients Get Wrong Blood Thinners for Angioplasty
Posted 9 Dec 2009 by Drugs.com
TUESDAY, Dec. 8 – More than one-fifth of patients on dialysis who undergo angioplasty are given blood thinners they should not be given, new research shows. As a result, these patients are subject to a higher rate of bleeding during their hospital stay and may even be at a higher risk of dying, according to a report in the Dec. 9 issue of the Journal of the American Medical Association. The drugs in question are enoxaparin (Lovenox), a low-molecular-weight heparin, and eptifibatide (Integrilin). The U.S. Food and Drug Administration (FDA) has determined that neither medication should be used in people undergoing dialysis. "The study does validate the FDA's directed labeling [of these drugs] as contraindicated, and it supports avoiding use of these drugs in dialysis patients," said study author Dr. Thomas Tsai, director of interventional cardiology at the Denver VA Medical Center and an ... Read more
Related support groups: Lovenox, Enoxaparin, Clexane, Eptifibatide, Integrilin, Lovenox HP, Clexane Forte, Hemodialysis Anticoagulation
FDA Medwatch Alert: Lovenox (enoxaparin sodium injection)
Posted 17 Aug 2004 by Drugs.com
FDA and Aventis Pharmaceuticals revised the CLINICAL PHARMACOLOGY, PRECAUTIONS, and DOSAGE AND ADMINISTRATION sections of labeling, describing the need for a dosage adjustment for patients with severe renal impairment (creatinine clearance <30mL/min) who have increased exposure to enoxaparin. No specific dosage adjustment is required in patients with mild or moderate renal impairment and in low-weight patients. However, low-weight patients should be observed carefully for signs and symptoms of bleeding.[March 2004 Letter - Aventis][July 2004 Label - Aventis] Read more
Related support groups: Lovenox, Lovenox HP
FDA Medwatch Alert: Lovenox (enoxaparin sodium)
Posted 3 Apr 2002 by Drugs.com
FDA and Aventis strengthened the WARNINGS and PRECAUTIONS sections of the Lovenox prescribing information to inform healthcare professionals that the use of Lovenox Injection is not recommended for thromboprophylaxis in patients with prosthetic heart valves. New postmarketing safety information concerning congenital anomalies and non-teratogenic effects on pregnant women and fetuses are described.[Feb 28, 2002 Letter - Aventis][July, 2001 Revised Label - Aventis] Changes highlighted Read more
Related support groups: Lovenox, Lovenox HP
Ask a Question
Further Information
Related Condition Support Groups
Deep Vein Thrombosis (DVT), Deep Vein Thrombosis, Deep Vein Thrombosis -- Prophylaxis, Acute Coronary Syndrome, Angina, Heart Attack, Myocardial Infarction, Deep Vein Thrombosis Prophylaxis after Hip Replacement Surgery, Deep Vein Thrombosis Prophylaxis after Abdominal Surgery, Deep Vein Thrombosis Prophylaxis after Knee Replacement Surgery